Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
18.05
+0.06 (0.33%)
Feb 11, 2026, 11:24 AM EST - Market open
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
$212,321
Profits / Employee
-$1,261,012
Market Cap
2.35B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ultragenyx Pharmaceutical | 1,294 |
| Recursion Pharmaceuticals | 800 |
| Ascentage Pharma Group International | 605 |
| Galapagos NV | 558 |
| Ocular Therapeutix | 325 |
| Harmony Biosciences Holdings | 268 |
| Soleno Therapeutics | 152 |
MESO News
- 5 hours ago - Mesoblast: Real-World Data Validates The Bull Case For Ryoncil - Seeking Alpha
- 13 days ago - Ryoncil® Net Revenues Increase for the Quarter to US$30M - GlobeNewsWire
- 15 days ago - Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment - GlobeNewsWire
- 23 days ago - FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy - GlobeNewsWire
- 4 weeks ago - Ryoncil® Sales Increase 60% in December Quarter to US$35.1M - GlobeNewsWire
- 5 weeks ago - Mesoblast Announces Changes to Board of Directors' Leadership Roles - GlobeNewsWire
- 6 weeks ago - Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line - GlobeNewsWire
- 2 months ago - Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD - GlobeNewsWire